GlassScriptPhysician profile
Chandra K Ponniah
NPI 1881858405
$4,358.93
in general payments reported to CMS, 2019-2025
36 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $696 · 2021: $1,077 · 2022: $811 · 2023: $522 · 2024: $549 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,525 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,524.98 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $673.48 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $635.68 | 2019-2024 | Repatha, Evenity, Prolia |
| Novo Nordisk INC | $438.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $379.57 | 2020-2024 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $361.40 | 2020-2025 | |
| Amarin Pharma, INC. | $218.59 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.99 | 2020-2024 | Tradjenta, Synjardy, Jardiance |
| Merck Sharp & Dohme LLC | $193.76 | 2021-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Pfizer INC. | $173.31 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $154.07 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $114.14 | 2023-2024 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $103.61 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $93.38 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $58.64 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $54.29 | 2022-2023 | Austedo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zealand Pharma US, INC. | $52.90 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.79 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $42.40 | 2021-2022 | |
| Biogen, INC. | $35.73 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $31.31 | 2022 | |
| Daiichi Sankyo INC. | $30.43 | 2022 | |
| Janssen Pharmaceuticals, INC | $27.59 | 2021 | |
| Grifols USA, LLC | $26.15 | 2022 | |
| Dexcom, INC. | $24.44 | 2022 | |
| Mannkind Corporation | $20.00 | 2023 | Afrezza |
| Seqirus USA INC | $18.84 | 2025 | Flucelvax |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.45 | 2025 | Caplyta |
| Ironwood Pharmaceuticals, INC | $17.19 | 2020 | |
| Sanofi Pasteur INC. | $17.14 | 2021 | |
| Genentech USA, INC. | $16.44 | 2020 | |
| Acadia Pharmaceuticals INC | $15.97 | 2023 | Nuplazid |
| Mylan Specialty L.P. | $14.94 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.32 | 2021 | |
| Glaxosmithkline, LLC. | $13.76 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.61 | 2020 | |
| Phathom Pharmaceuticals, INC. | $11.73 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandra Ponniah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.